Semaglutide 2.4 mg
Cross-source consensus on Semaglutide 2.4 mg from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Benefits
Dosage & preparation
Highlighted claims
- Semaglutide produced much greater percentage body weight loss than placebo at 68 weeks. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- BARI-STEP tested semaglutide 2.4 mg once weekly plus lifestyle intervention in adults with poor weight loss after gastric bypass or sleeve gastrectomy. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Semaglutide produced greater absolute body weight reduction than placebo. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Most semaglutide participants achieved clinically meaningful categorical weight-loss thresholds. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- All semaglutide participants who completed the trial reached the 2.4 mg target dose. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial